effects of a 9 day course of treatment with either the Hh pathway inhibitor GDC-0449 or vehicle (DMSO) on expression of (C) TGFb and (D) PDGFb in Mdr22/2 mice (n = 5 mice/group). Gene expression was normalized to expression of S9 in the same samples; mean +/2 SEM values were calculated; values in the experimental groups were graphed relative those in the respective controls. P values are shown. (TIF) Table S1 (PDF) References 1. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, et al. (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453–469. 2. Luedde T, Schwabe RF (2011) NF-kappaB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108–118. 3. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838–851. 4. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, et al. (2009) Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci 14: 4242–4256. 5. Jacquemin E (2001) Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 21: 551–562. 6. Trauner M, Fickert P, Halilbasic E, Moustafa T (2008) Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 158: 542–548. 7. Trauner M, Fickert P, Wagner M (2007) MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27: 77–98. 8. Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, et al. (2008) Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int 28: 948–958. 9. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, et al. (2000) Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119: 1720–1730. 10. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, et al. (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127: 261–274. 11. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, et al. (2002) Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123: 1238–1251. 12. Frijters CM, Ottenhoff R, Van Wijland MJ, Van Nieuwkerk C, Groen AK, et al. (1996) Influence of bile salts on hepatic mdr2 P-glycoprotein expression. Adv Enzyme Regul 36: 351–363. 13. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D (2005) Mdr2 (Abcb4)2/2 mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43: 1045–1054. 14. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, et al. (1996) Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111: 165–171. 15. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, et al. (2007) Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res 5: 1159–1170. 16. Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, et al. (2006) Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res 66: 4001–4010. 17. Ramalho-Santos M, Melton DA, McMahon AP (2000) Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 127: 2763–2772. 18. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, et al. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846–851. 19. Omenetti A, Diehl AM (2008) The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver development, inflamma- tion, and cancer. Am J Physiol Gastrointest Liver Physiol 294: G595–598. 20. Omenetti A, Popov Y, Jung Y, Choi SS, Witek RP, et al. (2008) The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut 57: 1275–1282. 21. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, et al. (2008) Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118: 3331–3342. 22. Omenetti A, Yang L, Li YX, McCall SJ, Jung Y, et al. (2007) Hedgehog- mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest 87: 499–514. 23. Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, et al. (2009) Hedgehog- mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonal- coholic fatty liver disease. Gastroenterology 137: 1478–1488 e1478. 24. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, et al. (2009) Hedgehog pathway activation and epithelial-to-mesenchymal transitions during Hedgehog Pathway Inhibition in Liver Cancer Model Author Contributions Conceived and designed the experiments: GMP ISC VTS FR CL AMD. Performed the experiments: GMP ISC MS VTS CG GFK CM W-KS YJ RPW SC FR EM CL AMD. Analyzed the data: GMP ISC MS VTS CG TV SF W-KS SC GAM EM CL AMD. Contributed reagents/materials/ analysis tools: EM CL AMD. Wrote the paper: GMP ISC FR GAM SC AMD. myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 297: G1093–1106. 25. Sicklick JK, Li YX, Choi SS, Qi Y, Chen W, et al. (2005) Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest 85: 1368–1380. 26. Huang S, He J, Zhang X, Bian Y, Yang L, et al. (2006) Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27: 1334–1340. 27. Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, et al. (2006) Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 27: 748–757. 28. Patil MA, Zhang J, Ho C, Cheung ST, Fan ST, et al. (2006) Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 5: 111–117. 29. Chen W, Tang T, Eastham-Anderson J, Dunlap D, Alicke B, et al. (2011) Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A 108: 9589–9594. 30. Pereira Tde A, Witek RP, Syn WK, Choi SS, Bradrick S, et al. (2010) Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 90: 1690–1703. 31. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, et al. (2011) Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 17: 2502–2511. 32. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, et al. (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164–1172. 33. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361: 1173–1178. 34. Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, et al. (2009) Pan- caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50: 1421–1430. 35. Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271–1277. 36. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, et al. (2008) Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 13: 1155–1165. 37. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, et al. (2011) Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53: 106–115. 38. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, et al. (1994) Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145: 1237–1245. 39. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451–462. 40. Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, et al. (2010) Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59: 655–665. 41. Rangwala F, Guy CD, Lu J, Suzuki A, Burchette JL, et al. (2011) Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 224: 401–410. 42. Yang L, Wang Y, Mao H, Fleig S, Omenetti A, et al. (2008) Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol 48: 98–106. 43. Das S, Harris LG, Metge BJ, Liu S, Riker AI, et al. (2009) The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem 284: 22888–22897. 44. Omenetti A, Choi S, Michelotti G, Diehl AM (2011) Hedgehog signaling in the liver. J Hepatol 54: 366–373. 45. Machado MV, Cortez-Pinto H (2011) Osteopontin: a missing link between hedgehog signaling and fibrosis in nonalcoholic steatohepatitis. Hepatology 53: 382–384. 46. Rangwala F, Omenetti A, Diehl AM (2011) Cancer stem cells: repair gone awry? J Oncol 2011: 465343. PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e23943